Chronic obstructive pulmonary disease (COPD) is a lung disease, for which currently there is no cure. Patients with COPD develop persistent breathing difficulties and repeated exacerbations. Now, COPD is one of the leading causes of morbidity and the fifth-leading cause of death globally. COPD gets worse over time and it can be aggravated by a pathogen called nontypeable Haemophilus influenzae (NTHi). A recent study reveals that a natural compound called resveratrol can suppress inflammation caused by the bacterium NTHi. The study, led by scientists at Georgia State University and reported in Scientific Reports on 28 September, could lead to non-antibiotic treatments for COPD and many other NTHi-associated airway diseases. Resveratrol is a component of grapes, peanuts, red wine, and some other foods. It is a powerful antioxidant, and it's known to have health benefits. Although experiments in laboratory have indicated that resveratrol reduces inflammation, how it works is not completely understood. For the first time, the researchers discovered that resveratrol suppresses the bacterium NTHi through enhancing a negative regulator of inflammation, known as MyD88 short. Moreover, resveratrol has anti-inflammatory effects post NTHi infection. Collectively, the data reveal a mechanism by which resveratrol reduces NTHi-induced inflammation. The MyD88 protein acts as an adapter, connecting proteins that receive signals from outside the cell to the proteins that transmit signals inside the cell. The bacterium NTHi can cause various inflammatory diseases, such as asthma, otitis media and chronic obstructive pulmonary diseases. These airway diseases seriously threaten people's health and cause financial burden on medical system. Antibiotics are usually used to treat NTHi infections, but the increase of resistance to antibiotics presents an urgent need for novel non-antibiotic therapies. Described in Scientific Reports, the new study shows the possibility to use resveratrol or its derivatives as a treatment for these airway diseases. According lead author Dr. Jian-Dong Li, upregulating MyD88 short might be a new way of combating inflammation. On the other hand, previous research has shown that resveratrol may also prevent atherosclerosis, cancer, heart disease, high cholesterol. So resveratrol may have a wide application prospect in medical field. But it is necessary to research thoroughly resveratrol's working mechanisms. This study reveals one of the possible mechanisms of resveratrol benefits. CusAb, a manufacturer of proteins and antibodies, has the ability to offer high-quality products including Recombinant FGFR1 and MyD88.